Schering Corporation

Merck Sharp + Dohme Corp.

Pharmacopeia Drug Discovery, Inc.

Other

Pharmacopeia Inc.

Michael K C Wong

Joseph A Kozlowski

Wensheng Yu

Brian J Lavey

Guowei Zhou

Ling Tong

Bandarpalle B Shankar

Seong Heon Kim

De-Yi Yang

Neng-Yang Shih

Lei Chen

Dansu Li

Kristin E Rosner

M Arshad Siddiqui

Janeta Popovici-Muller

Vinay M Girijavallabhan

Razia Rizvi

Chaoyang Dai

Vincent Stewart Madison

Zhuyan Guo

Peter Orth

Robert Feltz

Stuart B Rosenblum

Brian F McGuinness

Douglas Walsh Hobbs

Qingbei Zeng

Gopinadhan N Anilkumar

Yuefei Shao

Judson E Richard

Aneta Maria Kosinski

Luke Fire

Youheng Shu

Aneta M Micula

Umar Faruk Mansoor

Richard J Friary

Liping Yang

Lisa Guise Zawacki

Seong-Heon Kim

John J Baldwin

William J Greenlee

Andrew William Stamford

Michael W Miller

Xing Dai

Duane E DeMong

Ginny Dai Ho

Guizhen Dong

R Jason Herr

W Michael Seganish

Yueheng Jiang

Larry Yet

Jinhai Yang

Stephanie Brumfield

Aneta Maria Kosinzki

Kristen E Rosner

Doublas W Hobbs

Shankar B Bandarpalle

Razia K Rizvi

James P Iii Harding

Deen B Tulshian

William T Mcelroy

Brian F Mc Guinness

This invention relates to compounds of the Formula (I) as described herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof. 

Compounds for the treatment of inflammatory disorders

This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof. 

This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF&#x2014;or combinations thereof. 

This invention relates to compounds of the Formula (I)-(IX):, as defined herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-&#x3b1; combinations thereof. 

Compounds for the treatment of inflammatory diseases

The present invention relates to compounds of the general formula: (I) wherein ring A, ring B, R, R, Z, L, and Lare selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto. 

Spiro-imidazolone derivatives as glucagon receptor antagonists

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

Heterocyclic substituted piperazines with CXCR3 antagonist activity

This invention relates to compounds of the Formula (I): 

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates or esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

Heteroaryl substituted pyrazinyl-piperazine-piperidines with CXCR3 antagonist activity

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity

Growing community of inventors

North Brunswick, NJ, United States of America

Michael K C Wong